The Mylan estradiol patch is a generic transdermal hormone therapy that delivers estradiol through the skin. It treats menopause symptoms including hot flashes, vaginal dryness, and osteoporosis prevention. Manufactured by Viatris, it carries full FDA approval and offers the same bioidentical estradiol as brand-name alternatives.
The Mylan patch is available in four dosage strengths: 0.025 mg, 0.05 mg, 0.075 mg, and 0.1 mg per day. It is applied once weekly, bypassing the digestive system and liver for steadier hormone delivery and a lower blood clot risk than oral estrogen. Most users report symptom relief within two to four weeks of starting therapy.
This review covers what the Mylan estradiol patch is, how it works, its dosages, side effects, safety warnings, and how it compares to other estradiol options. It also walks through proper application technique and what to expect from long-term use.
What Is the Mylan Estradiol Patch?
The Mylan estradiol patch is a once-weekly transdermal hormone replacement therapy that delivers bioidentical estradiol directly through the skin into the bloodstream. It is manufactured by Viatris (formerly Mylan) and sold under the Estradiol Transdermal Patches (Mylan) label. The patch is FDA-approved for several menopause-related indications.
The patch consists of a round adhesive system with a peach-colored outer disk printed with the dosage information in brown ink. Each patch is sealed in a square, notched pouch with the lot number and expiration date printed on the outside. The patch releases estradiol at a controlled rate throughout the seven-day wear period.
The Mylan formulation uses estradiol USP hemihydrate as the active ingredient. It is bioidentical, meaning the molecule is structurally identical to the estradiol the human body produces naturally. Generic versions like the Mylan patch must demonstrate bioequivalence to the original branded product before receiving FDA approval.
How Is Mylan Estradiol Patch Different from Brand-Name Patches?
The Mylan patch delivers the same bioidentical estradiol as brand-name options like Climara but typically costs significantly less due to its generic status. Viatris manufactures the Mylan patch to the same FDA bioequivalence standards as branded estradiol patches. The active ingredient, dosing mechanism, and clinical outcomes are clinically equivalent.
The primary difference is presentation. The Mylan patch uses a round dual-disk design rather than the rectangular or oval shapes used by some branded alternatives. Both formats deliver estradiol transdermally at the same rate per surface area. The choice between generic and brand-name is typically driven by cost and insurance coverage.
Insurance plans often list the Mylan generic as a preferred or lower-cost tier option compared to brand-name patches. Patients switching from a brand-name estradiol patch to the Mylan generic should expect similar clinical results. A prescribing provider can confirm therapeutic equivalence for the specific dosage required.
Who Manufactures the Mylan Estradiol Patch?
The Mylan estradiol patch is manufactured by Viatris Inc., the company formed by the 2020 merger of Mylan and Pfizer’s Upjohn division. New Zealand distribution is handled through Viatris Limited BGP Products (Upjohn New Zealand ULC). The product retains the ‘Mylan’ brand identity in its common name and patient-facing labeling.
Viatris is a global pharmaceutical company with established manufacturing standards for generic hormone therapies. The company issued an important update in August 2023, notifying healthcare professionals of an alternative registered carton for the Estradiol Transdermal Patches (Mylan) product. The change affected packaging presentation and the enclosed leaflet, not the formula.
Adverse events related to the Mylan estradiol patch should be reported to Viatris at medinfo_anz@viatris.com. In the United States, adverse events are reported through the FDA’s MedWatch program. Healthcare providers can access the current data sheet and consumer medicine information through official Viatris channels.
What Are the Approved Uses of Mylan Estradiol Patch?
The Mylan estradiol patch is FDA-approved for four primary indications related to estrogen deficiency and menopause. These include treating moderate to severe vasomotor symptoms, vulvar and vaginal atrophy, hypoestrogenism from specific causes, and prevention of postmenopausal osteoporosis. Each indication has specific prescribing guidelines.
FDA-Approved Indications:
- Treatment of moderate to severe vasomotor symptoms due to menopause (hot flashes, night sweats)
- Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause
- Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure
- Prevention of postmenopausal osteoporosis
The prescribing information specifies that when used solely for vaginal atrophy symptoms, topical vaginal products should be considered first. The transdermal system is reserved for women who require systemic estrogen delivery. A prescribing provider evaluates which indication applies and selects the appropriate starting dose.
The Mylan patch is not indicated for birth control and will not restore fertility. It is also not recommended for the long-term maintenance of general health or prevention of heart disease or dementia. These limitations are clearly outlined in both the FDA prescribing information and the New Zealand consumer medicine information leaflet.
Is Mylan Estradiol Patch Used for Osteoporosis Prevention?
Yes. The Mylan estradiol patch is approved for osteoporosis prevention in postmenopausal women, though prescribers must first consider non-estrogen medications for women seeking only this benefit. The FDA prescribing information specifies that estrogen therapy for osteoporosis prevention is limited to women at significant risk. Estradiol supports bone density by maintaining the hormonal environment that slows bone resorption.
Clinical studies referenced in the Mylan prescribing information include data on effects on bone mineral density in postmenopausal women. The Women’s Health Initiative studies also provide long-term data on the relationship between transdermal estrogen and bone health outcomes. Bone density benefits are an established secondary advantage for women already using the patch for symptom relief.
Women who use the Mylan estradiol patch primarily for osteoporosis prevention should have a documented risk assessment. Prescribers balance the skeletal benefit against the cardiovascular and cancer risks noted in the FDA’s black box warnings. Annual review of the ongoing need for therapy is standard clinical practice for this indication.
What Are the Dosage Strengths of Mylan Estradiol Patch?
The Mylan estradiol patch is available in four dosage strengths, ranging from 0.025 mg per day to 0.1 mg per day, applied once weekly. Each dosage corresponds to a specific patch size measured in square centimeters, with larger patches containing and releasing more estradiol per day. Dosing starts at the lowest effective level and is adjusted based on symptom response.
Mylan Estradiol Patch Dosage Strengths:
| Dosage | Patch Size | Total Estradiol Content | Wear Period |
| 0.025 mg/day | 7.75 cm2 | 0.97 mg | Once weekly |
| 0.0375 mg/day | 11.625 cm2 | 1.46 mg | Once weekly |
| 0.05 mg/day | 15.5 cm2 | 1.94 mg | Once weekly |
| 0.06 mg/day | 18.6 cm2 | 2.33 mg | Once weekly |
| 0.075 mg/day | Available | Per label | Once weekly |
| 0.1 mg/day | Available | Per label | Once weekly |
What Is the Starting Dose for Mylan Estradiol Patch?
The standard starting dose is one patch delivering 0.025 mg of estradiol per day, applied to the lower stomach or upper buttock area once weekly. According to the prescribing information for low estrogen treatment, this starting dose is the lowest available and allows the prescribing provider to titrate upward based on symptom control. Most providers also start at 0.025 mg for vasomotor symptoms and adjust after four to eight weeks.
Dose adjustments are made at follow-up appointments based on the severity of remaining symptoms and any side effects experienced. The 0.05 mg per day patch is the most commonly prescribed dose for moderate menopause symptoms. Higher doses of 0.075 mg or 0.1 mg per day are reserved for women with more severe or refractory symptoms.
The New Zealand consumer medicine information leaflet specifies dosages of 0.025 mg, 0.05 mg, 0.075 mg, and 0.1 mg per day. The treating physician determines which strength is appropriate based on the individual’s estrogen levels, symptom burden, and health history. Patients should not self-adjust the dosage without medical guidance.
What Do Mylan Estradiol Patch Reviews Say?
User reviews of the Mylan estradiol patch reflect the same satisfaction levels seen with branded estradiol patches, with users reporting effective symptom relief from hot flashes, improved sleep, and reduced vaginal dryness. The once-weekly format receives consistent praise for its low-maintenance routine compared to daily oral medications. Negative reviews center on skin irritation and the visibility of the patch under certain clothing.
Users who have switched from branded alternatives to the Mylan generic report equivalent therapeutic effects at a lower cost. The most common positive feedback pattern is symptom resolution within the first two to four weeks of starting therapy. Users describe this as a meaningful improvement in daily functioning and quality of life.
Critical feedback focuses on the circular patch design, which some users find more visible or harder to conceal than rectangular formats. Others report mild adhesion issues in hot or humid conditions. These complaints apply broadly to transdermal hormone therapy patches and are not unique to the Mylan formulation.
Is the Mylan Estradiol Patch as Effective as Vivelle-DOT or Climara?
Yes. The Mylan estradiol patch is therapeutically equivalent to branded options like Vivelle-DOT and Climara, as required by FDA bioequivalence standards for generic drug approval. The FDA mandates that generic transdermal estradiol systems demonstrate equivalent drug delivery rates and blood concentration profiles before approval. The Mylan patch meets this requirement.
Clinical outcomes including hot flash reduction, bone density effects, and symptom relief are equivalent across FDA-approved estradiol transdermal systems at matching dosage strengths. The difference between generic and brand-name is in inactive ingredients, patch shape, and price. Efficacy and safety profiles are the same.
Some patients report preferences for specific patch formats based on adhesion or skin feel rather than clinical outcomes. Switching between FDA-approved estradiol transdermal systems at the same dosage is generally considered safe. A prescribing provider can confirm therapeutic substitution for any specific clinical situation.
What Are the Side Effects of Mylan Estradiol Patch?
The side effects of the Mylan estradiol patch mirror those of all transdermal estradiol systems and are generally mild compared to oral estrogen therapy. The most frequently reported include skin irritation at the application site, breast tenderness, headaches, fluid retention, and nausea. Serious side effects are rare but documented and require immediate medical attention.
Common Side Effects:
- Skin irritation, redness, or itching at the application site
- Breast tenderness or enlargement
- Headaches (mild to moderate)
- Nausea or gastrointestinal discomfort
- Fluid retention
- Mood changes during the adjustment period
The FDA prescribing information for the Mylan estradiol patch lists additional precautions including exacerbation of hypertriglyceridemia, hypothyroidism, hypocalcemia, and endometriosis. Women with these conditions require closer monitoring during therapy. Visual abnormalities are a rare but documented adverse event requiring prompt evaluation.
Postmarketing experience reports are collected separately from clinical trial data in the Mylan prescribing information. These reports capture rare events not identified in controlled studies. Healthcare providers access this data through the FDA Adverse Event Reporting System and through Viatris pharmacovigilance channels.
Does the Mylan Estradiol Patch Increase Cancer Risk?
The FDA’s black box warning for the Mylan estradiol patch identifies increased risk of endometrial cancer in women with a uterus who use unopposed estrogen therapy. This risk is addressed by prescribing progestogen alongside estrogen for women who have not had a hysterectomy. Women without a uterus do not require concomitant progestogen therapy.
The black box warning also references breast cancer risk associated with estrogen and progestogen combination therapy, based on data from the Women’s Health Initiative studies. Breast cancer risk with estrogen-alone therapy was not significantly elevated in the WHI. The prescribing information section on malignant neoplasms provides detailed guidance on risk assessment.
Probable dementia risk is the third item in the black box warning, drawn from data in the Women’s Health Initiative Memory Study. This risk was observed in women 65 years and older using conjugated equine estrogens, not necessarily transdermal bioidentical estradiol. Prescribing providers weigh these warnings individually against the patient’s symptom burden and risk profile.
How Do You Apply the Mylan Estradiol Patch?
Applying the Mylan estradiol patch requires opening the sealed pouch when ready to apply, peeling the backing off the adhesive layer, and pressing the patch firmly onto clean, dry, hair-free skin on the lower stomach or upper buttock area. The application site must be free of powder, oil, or lotion. The patch is pressed in place with the hand for approximately 10 seconds to ensure adhesion.
Application Steps:
- Wash hands with soap and water before and after applying the patch.
- Tear open the pouch when ready to apply. Do not cut the pouch or the patch.
- Peel off the backing from the adhesive layer.
- Apply the patch to a clean, dry, hair-free area on the lower stomach or upper buttock.
- Press firmly with the hand for approximately 10 seconds.
- Smooth all edges to prevent early peeling.
The patch should not be applied to the breasts, over skin folds, on oily, broken, burned, or irritated skin, or on areas with skin conditions such as birthmarks or tattoos. The waistline should be avoided, as tight clothing in this area can rub the patch off prematurely. Applying a fresh patch to a different site each time prevents localized skin irritation.
Where Is the Best Place to Apply Mylan Estradiol Patch?
The best placement sites are the lower stomach below the navel and the upper buttock area, as specified in the FDA prescribing information and New Zealand consumer medicine information leaflet for Mylan estradiol patches. These flat areas provide stable skin surfaces with minimal friction, supporting consistent adhesion throughout the seven-day wear period. Both sites allow reliable transdermal absorption.
Rotating between the lower stomach and upper buttock with each patch change prevents skin irritation from repeated exposure at the same spot. Even minor shifts within the same general area reduce the risk of cumulative irritation. The FDA labeling specifies that each new patch should be placed on a different area than the previous one.
Avoid areas of frequent movement, pressure from clothing, or direct sun exposure. The inner arm and lower back are sometimes used as alternative sites, though the FDA-approved labeling specifically references the lower stomach and upper buttock. Any deviation from labeled sites should be discussed with a prescribing provider.
What Should You Do If the Mylan Estradiol Patch Falls Off?
If the patch falls off, a new patch should be applied as soon as possible and worn until the next scheduled change day. The original patch change schedule should be maintained rather than resetting the schedule around the replacement date. Missing a patch change does not require doubling up with an extra patch.
If the missed patch change is discovered close to the next scheduled change date, the new patch can be applied at that time. Temporary breakthrough symptoms like increased hot flashes may occur during the lapse period. These symptoms resolve quickly once the replacement patch is applied and estradiol delivery resumes.
Adhesion issues are more common in hot or humid conditions, during vigorous exercise, or when the skin was not properly prepared before application. Ensuring the skin is completely clean, dry, and free of lotions before application significantly reduces the likelihood of the patch falling off prematurely.
Is Mylan Estradiol Patch FDA Approved?
Yes. The Mylan estradiol patch is fully FDA-approved for four menopause-related indications and meets all federal bioequivalence requirements for generic transdermal estradiol therapy. The FDA approval process for generic patches requires clinical pharmacokinetic studies confirming equivalent estradiol blood concentrations compared to the reference product. The Mylan patch has passed these studies.
The Mylan prescribing information is available through the FDA’s DailyMed database, which currently lists 15 versions of the label reflecting updates over time. Each label revision reflects updated safety data or regulatory guidance from the FDA. Prescribers should reference the current approved label before initiating therapy.
The New Zealand regulatory approval is separate from the FDA approval and is governed by Medsafe, New Zealand’s medicines regulator. The Viatris communication from August 2023 notified healthcare professionals of a packaging change approved under New Zealand’s provisional consent process. The active formulation was not altered in that update.
What Are the Black Box Warnings for Mylan Estradiol Patch?
The FDA requires four black box warnings for the Mylan estradiol patch, covering endometrial cancer, cardiovascular disorders, probable dementia, and breast cancer. These warnings appear at the top of the prescribing information and apply broadly to estrogen-containing products. The specific risks and their magnitude vary by patient population and therapy type.
Endometrial cancer risk applies specifically to women with a uterus who use estrogen without concurrent progestogen therapy. Cardiovascular disorders include increased risk of deep vein thrombosis and pulmonary embolism. These risks led the FDA to recommend using the lowest effective dose for the shortest duration consistent with treatment goals.
The dementia warning references the Women’s Health Initiative Memory Study data from women 65 and older. The breast cancer warning draws primarily from the WHI data on combined estrogen-progestogen therapy. Prescribers discuss these risks with each patient before initiating therapy and document informed consent in the medical record.
How Much Does Mylan Estradiol Patch Cost?
The Mylan estradiol patch costs significantly less than branded estradiol patches like Climara because of its generic status, with typical retail prices ranging from $30 to $70 (USD) per month depending on dosage and pharmacy. Insurance plans frequently place the Mylan generic on a preferred tier, reducing out-of-pocket costs further. HSA and FSA accounts can be used for purchase.
Pharmacy pricing varies by location and discount programs. GoodRx and similar prescription discount cards can reduce the cost of the Mylan patch at participating pharmacies. Some telehealth platforms include generic estradiol patches as part of their bundled monthly prescription fee, which covers the consultation and delivery.
The cost advantage of generic over brand-name estradiol patches is substantial for uninsured patients or those on high-deductible plans. A 90-day supply of the Mylan estradiol patch often costs less than a single month’s supply of a branded equivalent. Prescribers can note ‘generic substitution permitted’ on the prescription to ensure the pharmacy dispenses the most cost-effective option.
Is Mylan Estradiol Patch Worth It?
The Mylan estradiol patch is worth it for women who need FDA-approved transdermal estradiol therapy and want the same clinical outcomes as branded patches at a lower cost. The Viatris formulation delivers bioidentical estradiol at the same bioequivalent rate as brand-name alternatives. The once-weekly format reduces the daily medication burden and maintains stable hormone levels throughout the wear period.
The primary advantages are cost savings over brand-name patches, FDA-verified bioequivalence, and the clinical benefits of transdermal estradiol over oral estrogen. The main limitations are the FDA’s black box warning requirements for all estrogen products and the need for medical supervision. Both are shared with every other estrogen therapy on the market.
Women who do best with the Mylan patch are those seeking a cost-effective, once-weekly HRT option with a documented safety and efficacy profile. A menopause-trained healthcare provider reviews individual health history, selects the appropriate starting dose, and monitors therapy over time. The Mylan estradiol patch represents a practical, evidence-backed entry point into transdermal hormone therapy.